"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Descriptor ID |
D016393
|
| MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
| Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 0 | 2 |
| 1994 | 3 | 1 | 4 |
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 1 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 3 | 5 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 0 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 6 | 0 | 6 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 0 | 5 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 4 | 0 | 4 |
| 2022 | 7 | 0 | 7 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Chronic Lymphocytic Leukemia With Two B-Cell Populations of Discordant Light Chain Restrictions in Individual Patients: Parallel Development of Biclonal B-Cell Neoplasms or Clonal Evolution With Isotype Switch? Am J Clin Pathol. 2023 04 04; 159(4):337-351.
-
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.
-
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
-
Numerous B cells in a mediastinal mass, but not a B-cell lymphoma. Blood. 2022 08 25; 140(8):932.
-
B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas. Hum Pathol. 2022 07; 125:48-58.
-
Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators. Haematologica. 2022 04 01; 107(4):966-969.
-
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
-
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582.
-
Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. Haematologica. 2022 01 01; 107(1):4-6.
-
Aggressive B-cell lymphomas with a primary bone marrow presentation. Histopathology. 2020 Sep; 77(3):369-379.